Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02597543 · ClinicalTrials.gov registry record · Phase 4
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
A Phase 4 study, sponsored by Paul Kim.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT02597543: Completed Phase 4 study, sponsored by Paul Kim.
NCT02597543 is a Phase 4 study that has completed, run by Paul Kim. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02597543, a Phase 4 study, has completed, sponsored by Paul Kim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal graft function. The investigators hypothesize that patients with nonspecific allograft dysfunction will demonstrate decreased myocardial perfusion reserve, related to microvascular allograft vasculopathy, compared to those with normal graft function.
Primary Outcome
Myocardial perfusion reserve calculates the increase in myocardial perfusion after stress in comparison to rest. Outcome measure time frame specifies when the myocardial perfusion reserve was obtained in relation to date of heart-transplant for each patient. This was a one time measurement made after heart-transplantation.
Interventions
- DRUG Gadolinium
- DRUG Regadenoson
- PROCEDURE Cardiac MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-06-30 |
| Phase | Phase 4 |
What the finished NCT02597543 record still lists
NCT02597543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Gadolinium is the first listed.
NCT02597543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02597543 about?
NCT02597543 is a clinical study titled "Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction". The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal graft function. The investigators hypothesize that patients with nonspec...
What is the current status of trial NCT02597543?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2015-11. Estimated completion is 2016-06-30.
What interventions are being tested in trial NCT02597543?
The interventions under investigation include: Gadolinium (DRUG), Regadenoson (DRUG), Cardiac MRI (PROCEDURE).
Who is sponsoring clinical trial NCT02597543?
This trial is sponsored by Paul Kim, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02597543's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia